Instability in the Middle East is pressuring pharmaceutical companies, impacting supply chains and clinical trials. Only 22% of firms were prepared, according to Argon & Co. The Middle East's pivotal role in logistics and energy exposes vulnerabilities in pharma's global network. Delayed transport, especially air freight, threatens the integrity of temperature-sensitive medicines like biologics and vaccines. Companies struggle to balance investment in resilience with profit margins.
Gen Li of Phesi reports over 4,300 global clinical trials are affected, notably Phase 3 trials. Large pharma companies, operating hundreds of sites in the region, are most susceptible. Patient safety and trial continuity remain top priorities during disruptions.